BACKGROUND: Estimating disease incidence from cross-sectional surveys, using biomarkers for "recent" infection, has attracted much interest. Despite widespread applications to HIV, there is currently no consensus on the correct handling of biomarker results classifying persons as "recently" infected long after the infections occurred. METHODS: We derive a general expression for a weighted average of recent incidence that-unlike previous estimators-requires no particular assumption about recent infection biomarker dynamics or about the demographic and epidemiologic context. This is possible through the introduction of an explicit timescale T that truncates the period of averaging implied by the estimator. RESULTS: The recent infection test dynamics can be summarized into 2 parameters, similar to those appearing in previous estimators: a mean duration of recent infection and a false-recent rate. We identify a number of dimensionless parameters that capture the bias that arises from working with tractable forms of the resulting estimator and elucidate the utility of the incidence estimator in terms of the performance of the recency test and the population state. Estimation of test characteristics and incidence is demonstrated using simulated data. The observed confidence interval coverage of the test characteristics and incidence is within 1% of intended coverage. CONCLUSIONS: Biomarker-based incidence estimation can be consistently adapted to a general context without the strong assumptions of previous work about biomarker dynamics and epidemiologic and demographic history.
BACKGROUND: Estimating disease incidence from cross-sectional surveys, using biomarkers for "recent" infection, has attracted much interest. Despite widespread applications to HIV, there is currently no consensus on the correct handling of biomarker results classifying persons as "recently" infected long after the infections occurred. METHODS: We derive a general expression for a weighted average of recent incidence that-unlike previous estimators-requires no particular assumption about recent infection biomarker dynamics or about the demographic and epidemiologic context. This is possible through the introduction of an explicit timescale T that truncates the period of averaging implied by the estimator. RESULTS: The recent infection test dynamics can be summarized into 2 parameters, similar to those appearing in previous estimators: a mean duration of recent infection and a false-recent rate. We identify a number of dimensionless parameters that capture the bias that arises from working with tractable forms of the resulting estimator and elucidate the utility of the incidence estimator in terms of the performance of the recency test and the population state. Estimation of test characteristics and incidence is demonstrated using simulated data. The observed confidence interval coverage of the test characteristics and incidence is within 1% of intended coverage. CONCLUSIONS: Biomarker-based incidence estimation can be consistently adapted to a general context without the strong assumptions of previous work about biomarker dynamics and epidemiologic and demographic history.
Authors: Michael P Busch; Christopher D Pilcher; Timothy D Mastro; John Kaldor; Gaby Vercauteren; William Rodriguez; Christine Rousseau; Thomas M Rehle; Alex Welte; Megan D Averill; Jesus M Garcia Calleja Journal: AIDS Date: 2010-11-27 Impact factor: 4.177
Authors: Wolfgang Hladik; Dennis Olara; Jonathan Mermin; David Moore; Willy Were; Lorraine Alexander; Robert Downing Journal: AIDS Res Hum Retroviruses Date: 2011-03-11 Impact factor: 2.205
Authors: Kelly A Curtis; M Susan Kennedy; Man Charurat; Abdulsalami Nasidi; Kevin Delaney; Thomas J Spira; S Michele Owen Journal: AIDS Res Hum Retroviruses Date: 2011-06-17 Impact factor: 2.205
Authors: Till Bärnighausen; Thomas A McWalter; Zachary Rosner; Marie-Louise Newell; Alex Welte Journal: Epidemiology Date: 2010-09 Impact factor: 4.822
Authors: Sarah L Braunstein; Denis Nash; Andrea A Kim; Ken Ford; Lambert Mwambarangwe; Chantal M Ingabire; Joseph Vyankandondera; Janneke H H M van de Wijgert Journal: PLoS One Date: 2011-04-12 Impact factor: 3.240
Authors: Katherine E Schlusser; Jacob Konikoff; Allison R Kirkpatrick; Charles Morrison; Tsungai Chipato; Pai-Lien Chen; Marshall Munjoma; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2017-03-20 Impact factor: 2.205
Authors: Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Hilmarie H Brand; Eric Arts; Immaculate Nankya; Robert A Salata; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2014-11-19 Impact factor: 2.205
Authors: Eduard Grebe; Alex Welte; Jake Hall; Sheila M Keating; Shelley N Facente; Kara Marson; Jeffrey N Martin; Susan J Little; Matthew A Price; Esper G Kallas; Michael P Busch; Christopher D Pilcher; Gary Murphy Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731
Authors: Reshma Kassanjee; Christopher D Pilcher; Michael P Busch; Gary Murphy; Shelley N Facente; Sheila M Keating; Elaine Mckinney; Kara Marson; Matthew A Price; Jeffrey N Martin; Susan J Little; Frederick M Hecht; Esper G Kallas; Alex Welte Journal: AIDS Date: 2016-09-24 Impact factor: 4.177
Authors: Gabor D Kelen; Yu-Hsiang Hsieh; Richard E Rothman; Eshan U Patel; Oliver B Laeyendecker; Mark A Marzinke; William Clarke; Teresa Parsons; Jordyn L Manucci; Thomas C Quinn Journal: AIDS Date: 2016-01-02 Impact factor: 4.177
Authors: Stéphanie Blaizot; Andrea A Kim; Clement Zeh; Benjamin Riche; David Maman; Kevin M De Cock; Jean-François Etard; René Ecochard Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205